FDA Drug Center Chief Tracy Beth Høeg Exits, Michael Davis Takes Over as Acting Director
Updated
Updated · Bloomberg · May 15
FDA Drug Center Chief Tracy Beth Høeg Exits, Michael Davis Takes Over as Acting Director
6 articles · Updated · Bloomberg · May 15
Tracy Beth Høeg left immediately as acting director of the FDA’s Center for Drug Evaluation, according to people familiar with the matter.
Michael Davis, the center’s current deputy director, is set to become acting director as the Trump administration begins reshaping the agency’s leadership.
The move is expected to be the first in a broader series of personnel changes aimed at giving the FDA a “clean slate” after former commissioner Marty Makary’s exit.
Høeg had been a key Makary ally, making her departure an early sign that the administration plans a wider reset at the agency.
Amidst leadership chaos and massive staff loss, can the FDA still ensure the safety of America's food and drugs?
How will the FDA maintain scientific integrity under a non-scientist leader for the first time in 50 years?
Will the push for innovative psychedelic treatments succeed despite the constant leadership turnover and political pressure?